BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23284752)

  • 1. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.
    Bobinet M; Vignard V; Rogel A; Khammari A; Dreno B; Lang F; Labarriere N
    PLoS One; 2012; 7(12):e51716. PubMed ID: 23284752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination.
    Rogel A; Vignard V; Bobinet M; Labarriere N; Lang F
    Cancer Immunol Immunother; 2011 Mar; 60(3):327-37. PubMed ID: 21080167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
    Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N
    Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context.
    Godet Y; Moreau-Aubry A; Mompelat D; Vignard V; Khammari A; Dreno B; Lang F; Jotereau F; Labarriere N
    Cancer Immunol Immunother; 2010 Mar; 59(3):431-9. PubMed ID: 19730858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
    Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
    Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
    Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
    J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
    Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
    PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
    Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
    Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.
    Godet Y; Moreau-Aubry A; Guilloux Y; Vignard V; Khammari A; Dreno B; Jotereau F; Labarriere N
    J Exp Med; 2008 Oct; 205(11):2673-82. PubMed ID: 18936238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.